ホーム 計算ツール
代理店ログイン

Covalent Inhibitor Library

カタログ番号 L9410
  ライブラリー構成化合物リスト   Excel SDF

Covalent inhibitors are small organic molecules which interact with specific target proteins and form a covalent bond, resulting an alteration of the protein conformation and subsequently inhibit the protein activity. With some exceptions, protein modification by covalent inhibitors is usually irreversible.

Covalent inhibitors possess significant advantages over non-covalent inhibitors, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. Consequently, there has been a reluctance to apply a covalent mode of action in drug discovery programs and avoided by the pharmaceutical industry.

Although the majority of successful covalent drugs were discovered through serendipity in phenotypic screens, and their molecular mechanisms were elucidated afterwards, covalent drugs have made a major impact on human health and have been highly successful drugs for the pharmaceutical industry over the last 100 years, such as penicillin, omeprazole, clopidogrel, aspirin, fluorouracil, and third generation of irreversible EGFR tyrosine kinase inhibitor AZD9291/Osimertinib.

In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. It appears that irreversible inhibitors may maintain activity against drug-resistant mutations that are acquired after treatment with reversible inhibitors. Irreversible inhibition has important and potentially advantageous consequences for drug pharmacodynamics in which the level and frequency of dosing relates to the extent and duration of the resulting pharmacological effect. The unique pharmacodynamic feature of covalent inhibitors might bring certain practical advantages. The prolonged duration of drug action on the target effectively uncouples the pharmacodynamics of the drug from the pharmacokinetics of exposure, as target inhibition persists after the drug has been cleared. This property of covalent drugs enables less frequent dosing and the potential for lower drug doses. In addition, more and more studies have found that many major diseases, such as malignant tumors, are regulated by kinases, and these enzymes have also become the most attractive drug targets. Over the past decade, covalent kinase inhibitors (CKI) have seen a resurgence in drug discovery. Current FDA approved CKIs will bring the dawn to cancer chemotherapy. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery.

The irreversible covalent inhibitor molecule is divided into two parts: a seeker and a warhead. After entering the body, the seeker and the target protein binding site first form a non-covalent interaction, and then the warhead forms an irreversible covalent bond with the nucleophilic residues of target protein. Common warheads include Michael acceptors, Sulfonyl fluoride, disulfide bond, etc.

The structure and mechanism of reversible covalent inhibitors are similar to irreversible covalent inhibitors, but the difference is that the covalent binding to the target protein is reversible. The warheads for reversible covalent inhibitors are reversible nucleophilic addition reaction receptors such as cyano group and ketone carbonyl group. The reversibility of its covalent binding to the target makes its pharmacokinetics fall in between irreversible covalent inhibitors and non-covalent inhibitors. To a certain extent, reversible covalent inhibitors share the advantages of irreversible covalent inhibitors in the prolonged duration of action and the potential for lower drug doses, while reducing the risk of toxicity caused by off-target.

TargetMol collects 1920 small molecules including identified covalent inhibitors and other molecules having covalent reactive groups as warheads, such as chloroacetyl,2-Chloropropionyl,Acryloyl,alkyne,sulfonyl fluoride, acrylamide, ketocarbonyl,disulfide bond, etc.

TargetMolの製品は全て研究用試薬です。人体にはご使用できません。 また、個人の方への販売は行っておりません。
パッケージサイズ
1 mg
30 μL * 10 mM (in DMSO)
50 μL * 10 mM (in DMSO)
100 μL * 10 mM (in DMSO)
250 μL * 10 mM (in DMSO)
If the above compound libraries do not match your needs,
please contact our compound library specialist for a customized compound library at [email protected]
ライブラリ構成化合物リストを依頼する
Get quote

製品概要

  • 共有結合性阻害剤として同定済みの化合物および反応性部位としてクロロアセチル基、2-クロロプロピオニル基、アクリロイル基、アルキニル基、フルオロスルフニル基、アクリルアミド、ケトカルボニル基、チオール基などの共有結合形成官能基を持つ化合物1920種類を当社が独自に収集
  • 化合物の構造は多様性に富み、一部の共有結合性阻害剤はFDA承認済み
  • 化合物の概要、化学構造、標的、IC50値、生物活性など詳細な情報を提供
  • NMRとHPLC/LCMSにより高純度と高品質を担保

ライブラリーのカスタマイズ

TargetMol社化合物ライブラリーは自由にカスタマイズできます! もっと詳しく

梱包・保管

  • バーコード付き貯蔵管や96/384-wellプレートに入っている粉末固体またはDMSO溶液
  • ブルーアイス同梱にて出荷
ライブラリ構成化合物複合リストをリクエスト (L9410)

Publications Cited TargetMol Libraries

隠し

ライブラリーの構成

Apoptosis (223)
Antibacterial (221)
Antibiotic (170)
Endogenous Metabolite (163)
Autophagy (137)
EGFR (73)
NF-κB (61)
Antifungal (38)
HIV Protease (37)
Reactive Oxygen Species (36)
Parasite (35)
VEGFR (34)
DNA/RNA Synthesis (30)
COX (29)
Influenza Virus (28)
BTK (28)
Dehydrogenase (27)
Proteasome (26)
PDGFR (25)
P450 (23)
FGFR (23)
Antioxidant (22)
Epigenetic Reader Domain (22)
Microtubule Associated (22)
Raf (22)
Estrogen/progestogen Receptor (21)
Calcium Channel (21)
STAT (20)
CDK (20)
Ferroptosis (20)
PI3K (19)
ERK (19)
c-Kit (19)
Ras (19)
AChR (19)
HDAC (18)
Caspase (18)
JAK (18)
Anti-infection (18)
Phosphatase (17)
Nucleoside Antimetabolite/Analog (17)
PKC (17)
p38 MAPK (17)
SARS-CoV (16)
TRP/TRPV Channel (16)
FLT (15)
mTOR (15)
BCL (15)
ribosome (15)
Akt (14)
Progesterone Receptor (14)
Cysteine Protease (14)
Potassium Channel (14)
ATPase (14)
PDE (13)
HSV (13)
Histone Methyltransferase (13)
Src (13)
HSP (12)
MAO (12)
IκB/IKK (12)
Monoamine Oxidase (12)
ROS (12)
HER (12)
Phospholipase (12)
MMP (11)
Adrenergic Receptor (11)
Antiviral (11)
TNF (11)
HCV Protease (11)
c-RET (11)
Glucocorticoid Receptor (11)
Tyrosinase (11)
Androgen Receptor (11)
AMPK (11)
HIF/HIF Prolyl-Hydroxylase (11)
Estrogen Receptor/ERR (10)
PPAR (10)
Drug Metabolite (10)
Nrf2 (10)
Wnt/beta-catenin (10)
AChE (10)
GABA Receptor (10)
DUB (10)
JNK (10)
5-HT Receptor (10)
TGF-beta/Smad (9)
HBV (9)
IL Receptor (9)
Virus Protease (9)
NOS (9)
Proton pump (9)
Reverse Transcriptase (8)
Mitophagy (8)
P-gp (7)
Mitochondrial Metabolism (7)
Trk receptor (7)
Prostaglandin Receptor (7)
Transferase (7)
RAAS (7)
E1/E2/E3 Enzyme (7)
Opioid Receptor (7)
P2Y Receptor (7)
PARP (7)
Bcr-Abl (7)
GluR (7)
Beta Amyloid (7)
NO Synthase (6)
S1P Receptor (6)
p53 (6)
Lipoxygenase (6)
Interleukin (6)
DNA Methyltransferase (6)
STING (6)
CCR (6)
MAPK (6)
HIF (6)
Chloride channel (6)
CXCR (6)
IRE1 (6)
Integrin (6)
Topoisomerase (6)
Glutathione Peroxidase (6)
Serine Protease (6)
c-Met/HGFR (6)
Tyrosine Kinases (6)
Reductase (6)
Antifection (5)
NOD (5)
Histone Acetyltransferase (5)
Cannabinoid Receptor (5)
Telomerase (5)
Retinoid Receptor (5)
NOD-like Receptor (NLR) (5)
PKA (5)
Sodium Channel (5)
Immunology/Inflammation related (5)
HMG-CoA Reductase (5)
IGF-1R (5)
Adenosine Receptor (5)
c-Fms (4)
CSF-1R (4)
Acyltransferase (4)
PERK (4)
Epoxide Hydrolase (4)
CaMK (4)
S6 Kinase (4)
Carbonic Anhydrase (4)
Indoleamine 2,3-Dioxygenase (IDO) (4)
Aurora Kinase (4)
ALK (4)
FAAH (4)
Hedgehog/Smoothened (4)
Pim (4)
Glucosidase (4)
PROTAC Linker (4)
BACE (4)
PLK (4)
DNA Alkylation (4)
DNA Alkylator/Crosslinker (4)
PDK (4)
DPP-4 (4)
Aryl Hydrocarbon Receptor (3)
Beta-Secretase (3)
GPR (3)
Hydroxylase (3)
LPL Receptor (3)
Isocitrate Dehydrogenase (IDH) (3)
CRISPR/Cas9 (3)
Histone Demethylase (3)
BCRP (3)
Dopamine Receptor (3)
Casein Kinase (3)
Gamma-secretase (3)
IRAK (3)
P2X Receptor (3)
GTPase (3)
GSK-3 (3)
Smo (3)
MEK (3)
Fatty Acid Synthase (3)
Thrombin (3)
TAM Receptor (3)
Mdm2 (3)
Aromatase (3)
iGluR (3)
DNA-PK (3)
ATM/ATR (3)
Histamine Receptor (2)
Pyroptosis (2)
MLK (2)
RSV (2)
GPX (2)
Ephrin Receptor (2)
Ligands for Target Protein for PROTAC (2)
CD73 (2)
Amino Acids and Derivatives (2)
c-Myc (2)
Aminopeptidase (2)
DprE1 (2)
Thyroid hormone receptor(THR) (2)
Acetyl-CoA Carboxylase (2)
EBI2/GPR183 (2)
CAT (2)
Lipid (2)
Decarboxylase (2)
Lipase (2)
ROR (2)
FLAP (2)
NAMPT (2)
Adenylyl cyclase (2)
FXR (2)
Leukotriene Receptor (2)
Glucagon Receptor (2)
Rho (2)
FAK (2)
MRP (2)
NMDAR (2)
Chk (2)
UGT (2)
cAMP (2)
RIP kinase (2)
Tie-2 (2)
ATP Citrate Lyase (2)
TLR (2)
OX Receptor (2)
PAK (2)
Adenosine deaminase (2)
transporter (2)
Sirtuin (2)
IDO (2)
LRRK2 (2)
Complement System (2)
Melanocortin Receptor (1)
MELK (1)
PROTACs (1)
Dynamin (1)
Aquaporin (1)
Hippo pathway (1)
CRM1 (1)
MALT (1)
Ligand for E3 Ligase (1)
DHFR (1)
PD-1/PD-L1 (1)
Transaminase (1)
ROS Kinase (1)
Oxytocin Receptor (1)
Cell wall (1)
Monocarboxylate transporter (1)
NADPH (1)
Arginase (1)
RAR/RXR  (1)
Glutaminase (1)
PKM (1)
Somatostatin (1)
Glucokinase (1)
RANKL/RANK (1)
Glutathione reductase (1)
PGE Synthase (1)
ROCK (1)
IAP (1)
DNA (1)
Myosin (1)
Xanthine Oxidase (1)
DNA gyrase (1)
Antifolate (1)
Vasopressin Receptor (1)
Neuropeptide Y Receptor (1)
VDAC (1)
Guanylate cyclase (1)
cell cycle arrest (1)
Monoamine Transporter (1)
Liver X Receptor (1)
Haspin Kinase (1)
PAFR (1)
SIK (1)
Serine/threonin kinase (1)
Free radical scavengers (1)
gp120/CD4 (1)
Neprilysin (1)
CFTR (1)
AhR (1)
cholecystokinin (1)
TOPK (1)
SGK (1)
ABC (1)
KLF (1)
PI4K (1)
NPC1L1 (1)
YAP (1)
CPT (1)
LTR (1)
ACK (1)
PAD (1)
PTEN (1)
Necroptosis (1)
Galectin (1)
Thioredoxin (1)
Bombesin Receptor (1)
MAGL (1)
cGAS (1)
Kinesin (1)

化合物ライブラリー情報実例

Empty 1000025-07-9 1000413-72-8 229005-80-5 1000787-75-6 946387-07-1 1000998-59-3 1175526-27-8 1001288-58-9 1001350-96-4 1001404-83-6 Empty
Vadadustat TAK875 TAK-779 Tegobuvir RN-1734 BMS-687453 AM211 FT011 BMS754807 AAI101
Empty 1001625-82-6 1001645-58-4 1001753-24-7 1001908-89-9 1002304-34-8 1002-84-2 100291-86-9 100299-08-9 10030-52-1 10040-45-6 Empty
RPW-24 SRT1720 hydrochloride INH6 SRT 2183 AMG208 Pentadecanoic acid Apiopaeonoside Pemirolast potassium L-Anserine nitrate salt Sodium Picosulfate
Empty 100427-26-7 1004316-88-4 10045-45-1 100462-37-1 1004990-28-6 100-51-6 1005-24-9 1005264-47-0 1005334-57-5 1005342-46-0 Empty
Lercanidipine Cobicistat 1-Ethyl-2-benzimidazolinone ROSIRIDIN PF-AKT400 Benzyl alcohol 1-Methylnicotinamide chloride MX69 CVT-10216 LCL161
Empty 1005491-05-3 100-55-0 1005504-62-0 1005883-72-6 100643-71-8 1007207-67-1 10075-50-0 1007647-73-5 100784-20-1 10083-24-6 Empty
Tirasemtiv Roniacol Rg3039 Z433927330 Desloratadine CH5132799 5-Bromoindole Smurf1-IN-A01 Halosulfuron-methyl Piceatannol
Empty 100872-83-1 100874-08-6 1009119-64-5 1009119-65-6 100929-71-3 1009298-09-2 1009298-59-2 100929-99-5 1009734-33-1 10097-84-4 Empty
ML346 SB 4 Daclatasvir Daclatasvir dihydrochloride NADPH (tetracyclohexanamine) AZD8055 Vistusertib PAβN dihydrochloride HZ1157 Rotundine
Empty 1009816-48-1 1009817-63-3 1009820-21-6 100986-85-4 101001-34-7 1010411-21-8 1010-60-2 1011244-68-0 1011301-27-1 1011529-10-4 Empty
Thiamet G B-AP15 Silmitasertib Levofloxacin Pamicogrel GSK369796 Dihydrochloride 2-Chloronaphthoquinone TFAP Tenovin3 Azvudine
Empty 101152-94-7 101155-02-6 1011557-82-6 1011-74-1 101-20-2 1012054-59-9 101-21-3 101-26-8 101303-98-4 1013101-36-4 Empty
Milnacipran hydrochloride BW-A78U Tenovin-6 DL-Normetanephrine hydrochloride Triclocarban CUDC101 Chlorpropham Mestinon Zacopride hydrochloride PF04691502
Empty 101-31-5 1013-69-0 1013750-77-0 1013753-99-5 10138-52-0 1013920-15-4 1013937-63-7 1014691-61-2 101477-54-7 101494-95-5 Empty
L-Hyoscyamine Noreugenin ML-030 BC-1382 Gadolinium chloride Vorolanib VTP-27999 TFA GSK0660 Lomerizine hydrochloride 8-CHLOROQUINAZOLIN-4(1H)-ONE